The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2015

Filed:

Dec. 07, 2010
Applicants:

Holbrook Kohrt, Santa Clara, CA (US);

Roch Houot, Rennes, FR;

Ronald Levy, Stanford, CA (US);

Arash Ash Alizadeh, San Mateo, CA (US);

Matthew J. Goldstein, Hillsborough, CA (US);

James Torchia, Stanford, CA (US);

Inventors:

Holbrook Kohrt, Santa Clara, CA (US);

Roch Houot, Rennes, FR;

Ronald Levy, Stanford, CA (US);

Arash Ash Alizadeh, San Mateo, CA (US);

Matthew J. Goldstein, Hillsborough, CA (US);

James Torchia, Stanford, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2887 (2013.01); A61K 2039/507 (2013.01); C07K 16/2863 (2013.01); C07K 16/2878 (2013.01); C07K 16/32 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/75 (2013.01);
Abstract

Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.


Find Patent Forward Citations

Loading…